Robert Long, MD
Interventional Pain Medicine · Mankato, MNNPI 1407870272
Payments from drug & device makers
What this record shows
3 manufacturers reported payments, led by Abbott at 57.7% of the total. That places this record below the midpoint for interventional pain medicine clinicians in MN, where the typical reported total is $2,257.
Across 14 payments — averaging $63.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$515
- Nevro Corp.$360
- Boston Scientific$18
What the payments were for
- Travel & lodging$48755%
- Food & beverage$40545%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 3 | $515 |
| Nevro Corp. | 10 | $360 |
| Boston Scientific | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PROCLAIM$478
How this compares
$892 in reported general payments places this provider in the 35th percentile of 26 interventional pain medicine providers in Minnesota.
See all interventional pain medicine providers in Minnesota →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BelbucaBuprenorphine Hcl | 398 | $164,549 |
| Buprenorphine | 411 | $115,081 |
| Pregabalin | 412 | $20,851 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 68 | $16,729 |
| ButransBuprenorphine | 14 | $4,072 |
| Gabapentin | 128 | $3,616 |
| Oxycodone Hcl | 335 | $3,519 |
| OxycontinOxycodone Hcl | 22 | $2,964 |
| Tizanidine Hcl | 109 | $2,316 |
| Baclofen | 39 | $2,150 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 142 | $1,706 |
| Tramadol Hcl | 160 | $1,491 |
| Methocarbamol | 71 | $999 |
| Meloxicam | 41 | $742 |
| Fentanyl | 11 | $696 |
Paid to pharmacies, not to this prescriber.
Other interventional pain medicine in Mankato
- Ifechi AnyadiohaMankato$4K
- Gabriel Pagani-EstevezRochester$179K
- Nima AdimiChaska$114K
- Ryan BirklandRochester$15K
- James ParmeleMaple Grove$13K
- Jason WolffMaple Grove$9K
- Gregory CrewdsonMaplewood$8K
- Jasvinder SinghMaplewood$6K
- Gabriel SmithRochester$5K
- Nicholas CanzanelloRochester$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.